Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component

Prenatal Diagnosis

Volumn 20, Issue 5, 2000, Pages 395-399

  Moroz, C ^a,c   Maymon, R ^a   Jauniaux, E ^d   Traub, L ^a   Cuckle, H ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c RABIN MEDICAL CENTER   (Israel)

^d NONE

Author keywords

Down's syndrome; p43; Pregnancy; Serum screening

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; ISOFERRITIN;

ANALYTICAL EQUIPMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOWN SYNDROME; EDWARDS SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC SCREENING; HUMAN; MATERNAL SERUM; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS; TRISOMY 18; TRISOMY 21;

EID: 0034065831     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0223(200005)20:5<395::AID-PD837>3.0.CO;2-X     Document Type: Article

References (27)

1. Barkai G, Goldman B, Ries L. Chaki R, Zer T, Cuckle H. 1993. Expanding multiple marker screening for Down's syndrome to include Edwards' syndrome. Prenat Diagn 13: 843-850.
2. Brown PJ, Johnson PM, Ogbimi AO, Tappin JA. 1979. Characterization and localization of human placental ferritin. Biochem J 182: 763-769.
3. Cuckle HS. 1995. Improved parameters for risk estimation in Down's syndrome screening. Primal Diagn 15: 1057-1065.
4. Cuckle HS. 1996. Established markers in second trimester maternal serum. Early Hum Dev 47 (Suppl): 27-29.
5. Cuckle HS, van Lith JM. 1999. Appropriate biochemical parameters in first trimester screening for Down's syndrome. Prenat Diagn 19: 505-512.
6. Cuckle HS, Wald NJ, Thompson SG. 1987. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 94: 387-402.
7. Fisch B, Manor Y, Ovadia J, Moroz C. 1996. Placental isoferritin as a marker of early abortion in pregnancies induced in vitro fertilization. Placenta 17: 247-251.
8. Garty B, Zingerman B, Kaminsky E, Moroz C. 1997. High serum levels of placental isoferritin p43 component in Down's Syndrome. Children's Hosp Quarterly 9: 95-97.
9. Hayes C, Johnson Z, Thornton L, Fogarty J, Lyons R, O'Connor M, Delany Y, Buckley K. 1997. Ten year survival of Down's syndrome. Int J Epidemiol 26: 822-829.
10. Lamert-Messerlian GM, Saller DN, Tumber MB, French CA, Peterson CJ, Canick JA. 1998. Second trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner's syndrome with and without hydrops. Prenat Diagn 18: 1061-1067.
11. Maymon R, Moroz Z. 1996. Placental isoferritin: a new biomarker from conception to delivery. Br J Obstet Gynaecol 103: 301-305.
12. Maymon R, Bahary C, Moroz C. 1989. Placental isoferritin: a new serum marker in toxaemia of pregnancy. Am J Obstet Gynecol 160: 681-684.
13. Maymon R, Weinraub Z, Bukovsky I, Moroz CH. 1995. Placental isoferritin levels during first trimester of normal and complete molar pregnancies. Placenta 16: 455-460.
14. Maymon R, Ziter P, Manor Y, Bukovsky I, Moroz C. 1995a. Placental isoferritin patterns during normal first trimester and tubal gestations. Hum Reprod 10: 2445-2447.
15. Maymon R, Bar J, Halperin R, Bukovsky I, Moroz C. 1996b. Placental isoferritin patterns during first trimester intrauterine gestations. Gynecol Obstet Invest 42: 271-273.
16. Maymon R, Bar J. Sherman D, Moroz C. 1998a. Placental isoferritin levels in pregnant patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Am J Reprod Immunol 40: 95-101.
17. Maymon R, Jauniaux E, Bar J. Moroz C. 1998b. Maternal serum placental isoferritin levels in pregnant women with abnormal uterine artery Doppler velocemetry. Am J Perinatology 15 (11): 607-612.
18. Moroz C, Kupfer B, Twig S, Parhami-Seren B. 1985. Preparation and characterization of mononuclear antibodies specific to placental ferritin. Clin Chim Acta 114: 111-118.
19. Moroz C, Bessler H, Lurie Y, Shaklai M. 1987. A new monoclonal antibody enzymoassay for the specific measurement of placenta-like ferritin in haematologic malignancies. Exp Haematol 15: 258-262.
20. Moroz C, Misrock S, Siegal FP. 1989a. Isoferritins in HIV infection: relation to clinical stage CD8 lymphocyte binding and the pathogenesis of AIDS. AIDS 3: 11-16.
21. Moroz C, Shterman N, Kupfer B, Ginzburg I. 1989b. T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin. Proc Natl Acad Sci U S A 86: 3282-3285.
22. Murphy M, Epstein LB. 1990. Down Syndrome (trisomy 21) thymuses have a decreased proportion of cells expressing high levels of TCR alpha: beta and CD3 possible mechanism for diminished T cell function in Down Syndrome. Clin Immunol Immunopathol 55: 453-467.
23. Office of Population Censuses and Surveys. 1993. Birth Statistics Series FMI 7: 20-24.
24. Palomaki GE, Haddow JE, Knight GJ, Wald NJ, Kennard A, Canick JA, Saller DN, Blitzer MG, Dickerman LH, Fisher R. 1995. Risk based prnatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. Prenat Diagn 15: 713-723.
25. Royston P, Thompson SG. 1992. Model-based screening by risk with application to Down's syndrome. Stat Med 11: 257-268.
26. Thilaganathan B, Meher-Homji NJ, Nicolaides KH. 1995. Blood transferin receptor expression in chromosomally abnormal fetuses. Prenat Diagn 15: 282-284.
27. Ugazio AG, Maccariio R, Notaaromgelo LD, Burgio GR, 1990. Immunology of Down syndrome: a review. Am J Med Genet 7 (Suppl): 204-212.